Pediatrix Medical Group, Inc. (NYSE:MD) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP reduced its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 80.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,505 shares of the company’s stock after selling 87,931 shares during the period. GSA Capital Partners LLP’s holdings in Pediatrix Medical Group were worth $249,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MD. Aristeia Capital L.L.C. acquired a new position in shares of Pediatrix Medical Group in the second quarter worth about $687,000. Vanguard Group Inc. boosted its holdings in Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock valued at $105,892,000 after purchasing an additional 164,333 shares during the last quarter. Boston Partners boosted its holdings in Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after purchasing an additional 453,254 shares during the last quarter. Rubric Capital Management LP boosted its holdings in Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in Pediatrix Medical Group in the 2nd quarter valued at about $1,721,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Truist Financial upped their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. StockNews.com downgraded shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, Jefferies Financial Group increased their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $16.10.

Insiders Place Their Bets

In related news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. This represents a 18.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James D. Swift sold 11,100 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the transaction, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at $1,834,310.79. This represents a 6.13 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 53,808 shares of company stock worth $751,277 over the last three months. 2.00% of the stock is owned by insiders.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $14.96 on Friday. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -4.89, a price-to-earnings-growth ratio of 2.10 and a beta of 1.55. The business has a fifty day moving average of $12.93 and a 200-day moving average of $10.04. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.29 earnings per share. As a group, analysts predict that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.